PT1355668E - Utilização de inibidores da il-18 para o tratamento e/ou prevenção de doença cardíaca - Google Patents

Utilização de inibidores da il-18 para o tratamento e/ou prevenção de doença cardíaca Download PDF

Info

Publication number
PT1355668E
PT1355668E PT02718052T PT02718052T PT1355668E PT 1355668 E PT1355668 E PT 1355668E PT 02718052 T PT02718052 T PT 02718052T PT 02718052 T PT02718052 T PT 02718052T PT 1355668 E PT1355668 E PT 1355668E
Authority
PT
Portugal
Prior art keywords
inhibitors
prevention
treatment
heart disease
heart
Prior art date
Application number
PT02718052T
Other languages
English (en)
Portuguese (pt)
Inventor
Charles Dinarello
Yolande Chvatchko
Benjamin Pomerantz
Leonid Reznikov
Alden Harken
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of PT1355668E publication Critical patent/PT1355668E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT02718052T 2001-01-29 2002-01-28 Utilização de inibidores da il-18 para o tratamento e/ou prevenção de doença cardíaca PT1355668E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01101959 2001-01-29

Publications (1)

Publication Number Publication Date
PT1355668E true PT1355668E (pt) 2008-01-04

Family

ID=8176323

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02718052T PT1355668E (pt) 2001-01-29 2002-01-28 Utilização de inibidores da il-18 para o tratamento e/ou prevenção de doença cardíaca

Country Status (31)

Country Link
US (1) US20040234523A1 (https=)
EP (1) EP1355668B1 (https=)
JP (2) JP4860897B2 (https=)
KR (1) KR100857376B1 (https=)
CN (1) CN1326562C (https=)
AR (1) AR032422A1 (https=)
AT (1) ATE380558T1 (https=)
BG (1) BG66483B1 (https=)
BR (1) BR0206819A (https=)
CA (1) CA2435466C (https=)
CY (1) CY1107203T1 (https=)
CZ (1) CZ305653B6 (https=)
DE (1) DE60224004T2 (https=)
DK (1) DK1355668T3 (https=)
EA (2) EA006767B1 (https=)
EE (1) EE05534B1 (https=)
ES (1) ES2295332T3 (https=)
HR (1) HRP20030609A2 (https=)
HU (1) HU229164B1 (https=)
IL (2) IL157024A0 (https=)
ME (1) ME00549B (https=)
MX (1) MXPA03006776A (https=)
NO (1) NO331083B1 (https=)
PL (1) PL213568B1 (https=)
PT (1) PT1355668E (https=)
RS (1) RS51125B (https=)
SI (1) SI1355668T1 (https=)
SK (1) SK287620B6 (https=)
UA (1) UA80676C2 (https=)
WO (1) WO2002060479A1 (https=)
ZA (1) ZA200305439B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399148A1 (en) 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
JP2004528010A (ja) 2000-10-11 2004-09-16 バイロン・セラピューティックス・インコーポレーテッド 免疫モジュレーションのための核酸およびポリペプチド
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
US20080076708A1 (en) 2003-05-13 2008-03-27 Valter Altarocca Active Variants of the Il-18 Binding Protein and Medical Uses Thereof
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP4961559B2 (ja) * 2004-03-11 2012-06-27 友昭 星野 インターロイキン１８阻害剤を有効成分とする疾患の予防又は治療剤
AU2006254103B2 (en) 2005-06-03 2012-09-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
AU2006256763B2 (en) 2005-06-10 2012-08-02 Ares Trading S.A. Process for the purification of IL-18 binding protein
WO2009061832A1 (en) * 2007-11-05 2009-05-14 Kci Licensing Inc. Identification of tissue for debridement
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
UA125204C2 (uk) * 2013-09-05 2022-02-02 Аб2 Біо Са Застосування il-18-зв'язувального білка (il-18bp) при запальних захворюваннях
US10882905B2 (en) 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
WO2018013509A1 (en) * 2016-07-11 2018-01-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
AU738048B2 (en) * 1996-09-12 2001-09-06 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors
ATE346085T1 (de) * 1996-12-06 2006-12-15 Vertex Pharma Inhibitoren des interleukin-1-beta konvertierenden enzyms
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE19743687C1 (de) * 1997-10-06 1998-11-26 Henkel Kgaa Detergensgemische und deren Verwendung
WO2000000490A2 (en) * 1998-06-26 2000-01-06 Eli Lilly And Company 5-ht1f agonists
KR100537558B1 (ko) * 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인터류킨-18 결합 단백질
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
AU3876600A (en) * 1999-03-16 2000-10-04 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
US6355618B1 (en) * 1999-04-09 2002-03-12 Cytovia, Inc. Caspase inhibitors and the use thereof
AU6078500A (en) * 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
CZ300792B6 (cs) * 2000-05-05 2009-08-12 Applied Research Systems Ars Holding N. V. Farmaceutický prostredek
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
CZ305653B6 (cs) 2016-01-27
DE60224004D1 (de) 2008-01-24
CA2435466C (en) 2012-04-03
WO2002060479A1 (en) 2002-08-08
CA2435466A1 (en) 2002-08-08
JP2009102354A (ja) 2009-05-14
ES2295332T3 (es) 2008-04-16
PL213568B1 (pl) 2013-03-29
JP4860897B2 (ja) 2012-01-25
EE200300328A (et) 2003-10-15
KR20030070143A (ko) 2003-08-27
SK287620B6 (sk) 2011-04-05
HK1062810A1 (en) 2004-11-26
HUP0303306A3 (en) 2005-12-28
AR032422A1 (es) 2003-11-05
ATE380558T1 (de) 2007-12-15
EA200300844A1 (ru) 2003-12-25
HUP0303306A2 (hu) 2004-01-28
ZA200305439B (en) 2004-07-15
EP1355668A1 (en) 2003-10-29
SI1355668T1 (sl) 2008-06-30
HRP20030609A2 (en) 2005-06-30
JP2004522748A (ja) 2004-07-29
MXPA03006776A (es) 2003-10-24
KR100857376B1 (ko) 2008-09-05
CY1107203T1 (el) 2012-11-21
RS51125B (sr) 2010-10-31
US20040234523A1 (en) 2004-11-25
DE60224004T2 (de) 2009-07-23
CZ20032335A3 (en) 2004-07-14
CN1326562C (zh) 2007-07-18
YU57803A (sh) 2006-05-25
SK10892003A3 (sk) 2004-02-03
EA200501549A1 (ru) 2006-04-28
PL366802A1 (en) 2005-02-07
IL157024A0 (en) 2004-02-08
HU229164B1 (en) 2013-09-30
IL157024A (en) 2014-02-27
BG108128A (bg) 2004-11-30
ME00549B (me) 2011-10-10
EA010180B1 (ru) 2008-06-30
EA006767B1 (ru) 2006-04-28
EE05534B1 (et) 2012-04-16
UA80676C2 (en) 2007-10-25
NO331083B1 (no) 2011-10-03
EP1355668B1 (en) 2007-12-12
NO20033228L (no) 2003-09-26
BG66483B1 (bg) 2015-03-31
DK1355668T3 (da) 2008-05-05
NO20033228D0 (no) 2003-07-16
BR0206819A (pt) 2004-02-03
CN1499982A (zh) 2004-05-26

Similar Documents

Publication Publication Date Title
SI1487541T1 (sl) Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja
AU2003290548A8 (en) Prevention and treatment of synucleinopathic disease
HUP0401127A3 (en) Treatment and diagnosis of macrophage disease
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL160389A0 (en) Use of flibanserin for the treatment of sexual disorders
AU2002367535A8 (en) Diagnosis and treatment of vascular disease
AU2003223579A8 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
EP1392292A4 (en) PYRANOINDAZOLES AND THEIR USE IN GLAUCOMA TREATMENT
PL372928A1 (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
SI1627639T1 (sl) Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
HRP20030609A2 (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
PL376894A1 (pl) Pochodne 4-(fenylopiperazynylometylo) benzamidu i ich zastosowanie do leczenia bólu lub zaburzeń żołądkowo-jelitowych
HUP0303236A3 (en) Carbamate compounds for use in the treatment of pain
GB0213869D0 (en) The treatment of pain
PL376895A1 (pl) Pochodne 4-(fenylopiperazynylometylo) benzamidu i ich zastosowanie do leczenia bólu lub zaburzeń żołądkowo-jelitowych
IL155237A0 (en) Combination therapy for the treatment of estrogen-sensitive disease
GB0101146D0 (en) Treatment of skin conditions
AU2002366195A8 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
AU2002365654A8 (en) Treatment of diseases via the skin
GB0108622D0 (en) Treatment and prevention of tissue damage
GB0121046D0 (en) The diagnosis and treatment of airways disease
AU2003294697A8 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain
GB0120253D0 (en) Treatment of neuroinflammatory disease